This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Folkins, C. Articles by Kerbel, R. S. Search for Related Content PubMed PubMed Citation Articles by Folkins, C. Articles by Kerbel, R. S.

Anticancer Therapies Combining Antiangiogenic and Tumor Cell Cytotoxic Effects Reduce the Tumor Stem-Like Cell Fraction in Glioma Xenograft Tumors

¹ Department of Molecular and Cellular Biology Research, Sunnybrook Health Sciences Centre, and ² Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; and ³ ImClone Systems, Inc., New York, New York

Requests for reprints: Robert S. Kerbel, Molecular and Cellular Biology Research, Sunnybrook Health Sciences Centre, S-217, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5. Phone: 416-480-5711; Fax: 416-480-5884; E-mail: Robert.Kerbel{at}swri.ca.

Vascular endothelial cells have been identified as a critical component of the neural stem cell niche, raising the possibility that brain tumor stem-like cells (TSLC) may also rely on signaling interactions with nearby tumor vasculature to maintain their stem-like state. The disruption of such a TSLC vascular niche by an antiangiogenic therapy could result in loss of stemness characteristics associated with intrinsic drug resistance and, thus, preferentially sensitize TSLC to the effects of chemotherapy. Considering these possibilities, we investigated the impact of antiangiogenic anticancer therapy on the TSLC fraction of glioma tumors. Athymic nude mice bearing s.c. tumor xenografts of the C6 rat glioma cell line were treated with either a targeted antiangiogenic agent, antiangiogenic schedules of low-dose metronomic chemotherapy, combination therapies of antiangiogenic agents and chemotherapy, or, for the purpose of comparison, a conventional cytotoxic schedule of maximum tolerated dose chemotherapy using cyclophosphamide. Targeted antiangiogenic therapy or cytotoxic chemotherapy did not reduce the fraction of tumor sphere-forming units (SFU) in the tumor, whereas all treatment groups that combined both antiangiogenic and cytotoxic drug effects caused a significant reduction in SFU. This work highlights the possibility that selective eradication of TSLC may be achieved by targeting the tumor microenvironment (and potentially a supportive TSLC niche) rather than the TSLC directly. Furthermore, this work suggests a possible novel effect of antiangiogenic therapy, namely, as a chemosensitizer of TSLC, and thus represents a possible new mechanism to explain the ability of antiangiogenic therapy to enhance the efficacy of chemotherapy. [Cancer Res 2007;67(8):3560–4]

This article has been cited by other articles:

				C. Folkins, Y. Shaked, S. Man, T. Tang, C. R. Lee, Z. Zhu, R. M. Hoffman, and R. S. Kerbel Glioma Tumor Stem-Like Cells Promote Tumor Angiogenesis and Vasculogenesis via Vascular Endothelial Growth Factor and Stromal-Derived Factor 1 Cancer Res., September 15, 2009; 69(18): 7243 - 7251. [Abstract] [Full Text] [PDF]

				A. S. Chi, A. G. Sorensen, R. K. Jain, and T. T. Batchelor Angiogenesis as a Therapeutic Target in Malignant Gliomas Oncologist, June 1, 2009; 14(6): 621 - 636. [Abstract] [Full Text] [PDF]

				D. H. Gutmann Using Neurofibromatosis-1 to Better Understand and Treat Pediatric Low-Grade Glioma J Child Neurol, October 1, 2008; 23(10): 1186 - 1194. [Abstract] [PDF]

				A. Idbaih, F. Ducray, M. Sierra Del Rio, K. Hoang-Xuan, and J.-Y. Delattre Therapeutic Application of Noncytotoxic Molecular Targeted Therapy in Gliomas: Growth Factor Receptors and Angiogenesis Inhibitors Oncologist, September 1, 2008; 13(9): 978 - 992. [Abstract] [Full Text] [PDF]

				S. Ning, J. A. Nemeth, R. L. Hanson, K. Forsythe, and S. J. Knox Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo Mol. Cancer Ther., June 1, 2008; 7(6): 1569 - 1578. [Abstract] [Full Text] [PDF]

				R. S. Kerbel Tumor Angiogenesis N. Engl. J. Med., May 8, 2008; 358(19): 2039 - 2049. [Full Text] [PDF]

				K. Mimori, T. Fukagawa, Y. Kosaka, Y. Kita, K. Ishikawa, T. Etoh, H. Iinuma, M. Sasako, and M. Mori Hematogenous Metastasis in Gastric Cancer Requires Isolated Tumor Cells and Expression of Vascular Endothelial Growth Factor Receptor-1 Clin. Cancer Res., May 1, 2008; 14(9): 2609 - 2616. [Abstract] [Full Text] [PDF]

				A. Ocana and A. Pandiella Identifying Breast Cancer Druggable Oncogenic Alterations: Lessons Learned and Future Targeted Options Clin. Cancer Res., February 15, 2008; 14(4): 961 - 970. [Abstract] [Full Text] [PDF]

				J. Ma and D. J. Waxman Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib Mol. Cancer Ther., January 1, 2008; 7(1): 79 - 89. [Abstract] [Full Text] [PDF]

				Y. Shaked and R. S. Kerbel Antiangiogenic Strategies on Defense: On the Possibility of Blocking Rebounds by the Tumor Vasculature after Chemotherapy Cancer Res., August 1, 2007; 67(15): 7055 - 7058. [Abstract] [Full Text] [PDF]

				U. Emmenegger, Y. Shaked, S. Man, G. Bocci, I. Spasojevic, G. Francia, A. Kouri, R. Coke, W. Cruz-Munoz, S. M. Ludeman, et al. Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice Mol. Cancer Ther., August 1, 2007; 6(8): 2280 - 2289. [Abstract] [Full Text] [PDF]